Therefore, adenosine signaling pathway has been targeted by inhibiting either CD73 or A2aR alone, or in combination with ICIs to overcome tumor-mediated immunosuppressive effects in NSCLC [97]. This evidence concerns the gene ADORA2A and non-small cell lung carcinoma.